793 Combined administration of the dual A2aR/A2bR antagonist etrumadenant with a reduced chemotherapy regimen leads to enhanced tumor efficacy and survival

• Daniel DiRenzo,
• Dana Piovesan,
• Sachie Marubayashi,
• Ferdie Soriano,
• Janine Kline,
• Matthew J Walters,
• Ruben Flores,
• Gonzalo Barajas

Affiliations

Daniel DiRenzo

Arcus Biosciences, Inc, Hayward, CA, USA

Dana Piovesan

Arcus Biosciences, Inc, Hayward, CA, USA

Sachie Marubayashi

Arcus Biosciences, Inc, Hayward, CA, USA

Ferdie Soriano

Arcus Biosciences, Inc, Hayward, CA, USA

Janine Kline

Arcus Biosciences, Inc., Hayward, CA, USA

Matthew J Walters

Arcus Biosciences, Inc, Hayward, CA, USA

Ruben Flores

Arcus Biosciences, Inc., Hayward, CA, USA

Gonzalo Barajas

Arcus Biosciences, Inc., Hayward, CA, USA